Freenome
Freenome develops blood-based tests for early cancer detection using its multiomics platform that combines computational biology, machine learning, and advanced genomics. The company has raised $1.35B in total funding including …
What Freenome Does
Freenome develops blood-based tests for early cancer detection using its multiomics platform that combines computational biology, machine learning, and advanced genomics. The company has raised $1.35B in total funding including a $254M Series E in February 2024 led by T.
Rowe Price and Fidelity Investments. Freenome's initial programs focus on colorectal and lung cancer with a pipeline of single-cancer and multi-cancer tests under development.
The company operates PREEMPT CRC (>40,000-participant study for colorectal cancer screening) and PROACT LUNG (up to 20,000 participants for lung screening validation). Setting a new pace for early cancer detection with the ease of a standard blood draw.
Sign in with your company email to claim and enrich this profile.
How Freenome compares in its category
Read our independently researched buyer's guides to see where Freenome sits against the other leading vendors, how the category works, and what to check before shortlisting.